SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SEC File Number 333-216292
NOTIFICATION OF LATE FILING
☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR
For Period Ended: November 30, 2021
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-Q
Transition Report on Form N-SAR
For the Transition Period Ended: _______________
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: _________
PART I - REGISTRANT INFORMATION
Full Name of Registrant
Instadose Pharma Corp.
Former Name if Applicable:
Address of Principal Executive Office (Street and Number):
5500 North Service Road, Suite 301,
City, State and Zip Code:
Burlington, Ontario, L7L 6W6.
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ☒
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
The subject annual report, semi-annual report, transition report on Forms 10-K, 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.
The disruptions in transportation, staffing, and technology systems which have occurred over the last six months to both the Company and the Company’s professional advisors along with the recent change in control have resulted in limited support from the Company’s staff and professional advisors. This has, in turn, delayed the Company’s ability to complete its financial statements and prepare the Report.
PART IV - OTHER INFORMATION
Name and telephone number of person to contact in regard to this notification:
J.M. Walker & Associates
Attorneys at Law
(Area Code) (Telephone number)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s): ☒ Yes ☐ No
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof: ☐ Yes ☒ No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Instadose Pharma, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2022
/s/ Alex Wyie
Chief Executive Officer